Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted Vaccine
Top Cited Papers
- 17 December 2009
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 361 (25) , 2424-2435
- https://doi.org/10.1056/nejmoa0907650
Abstract
The 2009 pandemic influenza A (H1N1) virus has emerged to cause the first pandemic of the 21st century. Development of effective vaccines is a public health priority.Keywords
This publication has 22 references indexed in Scilit:
- Pneumonia and Respiratory Failure from Swine-Origin Influenza A (H1N1) in MexicoNew England Journal of Medicine, 2009
- Reproducibility of Serologic Assays for Influenza Virus A (H5N1)Emerging Infectious Diseases, 2009
- Emergence of a Novel Swine-Origin Influenza A (H1N1) Virus in HumansNew England Journal of Medicine, 2009
- Trivalent MDCK cell culture-derived influenza vaccine Optaflu®(Novartis Vaccines)Expert Review of Vaccines, 2009
- Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccineProceedings of the National Academy of Sciences, 2009
- Cell-Based Influenza VaccinesDrugs, 2008
- Strategies for mitigating an influenza pandemicNature, 2006
- Cross‐Reactivity to Highly Pathogenic Avian Influenza H5N1 Viruses after Vaccination with Nonadjuvanted and MF59‐Adjuvanted Influenza A/Duck/Singapore/97 (H5N3) Vaccine: A Potential Priming StrategyThe Journal of Infectious Diseases, 2005
- Sialic acid receptor specificity on erythrocytes affects detection of antibody to avian influenza haemagglutininJournal of Medical Virology, 2003
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001